drugset / Trial / NCT04300127
Pioglitazone for Idiopathic Gastroparesis
NaSingle-groupOpen-labelTreatment
Summary
The principal objective of this pilot study will be to evaluate whether 8 weeks of treatment of pioglitazone will improve symptoms as measured by the Gastrointestinal Symptom Index (GCSI) in patients with Idiopathic Gastroparesis.
Timeline
- Start
- 2019-10-24
- Primary completion
- 2025-03-15
- Completion
- 2025-03-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pioglitazone | Small molecule | 30 mg | Oral |